TABLE 1:
Summary of immunohistochemical findings among sample cohort.
| Patient | Immunohistochemistry | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRTN | IHBN | Desmin | SMA | H-C | AE1/3 | WT1 | HMB45 | Mart-1 | AR | ER | |
| 1 | 5+ | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 5+ |
| 2 | 5+ | 1+ | 3+ | 2+ | 0 | 4+ | 5+ | 0 | 2+ | 2+ | 5+ |
| 3 | 5+ | 1+ | 1+ | N/A | 0 | 1+ | 5+ | 0 | 0 | 4+ | 5+ |
| 4 | 5+ | 1+ | 1+ | N/A | 1+ | 5+ | 5+ | 0 | 1+ | 1+ | 5+ |
AE1/A3 (pancytokeratin, AE1/AE3); AR (androgen receptor); CRTN (calretinin); ER (estrogen receptor); H-C (H-caldesmon); IHBN; N/A (not assessed); and, SMA (smooth muscle actin). Scoring of tumors was based on the percentage of positive cells (0: no staining; 1+: <5%; 2+: 5% to 25%; 3+: 26% to 50%; 4+: 51% to 75%; and 5+: 76% to 100%). NB: WT1 (nuclear staining).